Table 1. Logistic regression analysis for the associations between H19 polymorphisms and neuroblastoma risk.
| Genotype | Cases (n=393) | Controls (n=810) | P1 | Crude OR (95% CI) | P | Adjusted OR (95% CI)2 | P2 |
|---|---|---|---|---|---|---|---|
| rs2839698 (HWE = 0.090) | |||||||
| GG | 179 (45.55) | 365 (45.06) | 1.00 | 1.00 | |||
| AG | 175 (44.53) | 373 (46.05) | 0.96 (0.74–1.23) | 0.732 | 0.96 (0.75–1.24) | 0.754 | |
| AA | 39 (9.92) | 72 (8.89) | 1.11 (0.72–1.70) | 0.650 | 1.11 (0.73–1.71) | 0.624 | |
| Additive | 0.797 | 1.01 (0.84–1.22) | 0.890 | 1.02 (0.84–1.23) | 0.858 | ||
| Dominant | 214 (54.45) | 445 (54.94) | 0.874 | 0.98 (0.77–1.25) | 0.874 | 0.99 (0.77–1.26) | 0.901 |
| Recessive | 354 (90.08) | 738 (91.11) | 0.561 | 1.13 (0.75–1.70) | 0.561 | 1.14 (0.75–1.71) | 0.541 |
| rs3024270 (HWE = 0.159) | |||||||
| CC | 99 (25.19) | 213 (26.30) | 1.00 | 1.00 | |||
| CG | 203 (51.65) | 424 (52.35) | 1.03 (0.77–1.38) | 0.842 | 1.03 (0.77–1.38) | 0.829 | |
| GG | 91 (23.16) | 173 (21.36) | 1.13 (0.80–1.60) | 0.486 | 1.14 (0.80–1.61) | 0.472 | |
| Additive | 0.764 | 1.06 (0.89–1.27) | 0.494 | 1.07 (0.89–1.27) | 0.480 | ||
| Dominant | 294 (74.81) | 597 (73.70) | 0.682 | 1.06 (0.80–1.40) | 0.683 | 1.06 (0.81–1.40) | 0.667 |
| Recessive | 302 (76.84) | 637 (78.64) | 0.480 | 1.11 (0.83–1.48) | 0.480 | 1.11 (0.83–1.48) | 0.470 |
| rs217727 (HWE = 0.470) | |||||||
| GG | 186 (47.33) | 382 (47.16) | 1.00 | 1.00 | |||
| AG | 164 (41.73) | 342 (42.22) | 0.99 (0.76–1.27) | 0.907 | 0.98 (0.76–1.27) | 0.888 | |
| AA | 43 (10.94) | 86 (10.62) | 1.03 (0.68–1.54) | 0.898 | 1.02 (0.68–1.53) | 0.922 | |
| Additive | 0.979 | 1.00 (0.84–1.20) | 0.970 | 1.00 (0.84–1.20) | 0.997 | ||
| Dominant | 207 (52.67) | 428 (52.84) | 0.956 | 0.99 (0.78–1.26) | 0.956 | 0.99 (0.78–1.26) | 0.932 |
| Recessive | 350 (89.06) | 724 (89.38) | 0.865 | 1.03 (0.70–1.52) | 0.864 | 1.03 (0.70–1.52) | 0.884 |
| Combined effect of protective genotypes | |||||||
| 0 | 258 (65.65) | 551 (68.02) | 1.00 | 1.00 | |||
| 1-3 | 135 (34.35) | 259 (31.98) | 0.410 | 1.11 (0.86–1.44) | 0.410 | 1.11 (0.86–1.44) | 0.411 |
1
χ2 test for genotype distributions between neuroblastoma patients and cancer-free controls.
2
Adjusted for age and sex.